ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b

Additional presentations include clinical and independent preclinical studies evaluating ADCT-601 targeting AXL

LAUSANNE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held in San Diego, CA from April 5-10, 2024.

“We’re excited to share compelling preclinical data supporting the future clinical development of the next-generation ADCs in our solid tumor portfolio, including those targeting Claudin-6 and NaPi2b, at the AACR Annual Meeting,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. “We’re also looking forward to research from independent studies that highlight the potential of another investigational ADC, ADCT-601 targeting AXL.”

Details of ADC Therapeutics’ poster presentations are as follows:

Title: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6
Abstract: 3122
Session Title: Antibody-Drug Conjugates
Date and Time: Monday, April 8, 2024; 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 21; Board number 3

Title: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b
Abstract: 5085
Session Title: Novel Immunotherapies and Immune Modulation
Date and Time: Tuesday, April 9, 2024; 9:00 a.m. – 12:30 p.m. PT
Location: Poster Section 42; Board number 7

Title: Phase 1b Trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas
Abstract: CT059
Session Title: Phase I Clinical Trials 1
Date and Time: Monday, April 8, 2024; 9:00 a.m. – 12:30 p.m. PT
Location: Poster Section 48; Board number 9

Title: Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL
Abstract: 875
Session Title: Application of Bioinformatics to Cancer Biology 1
Date and Time: Sunday, April 7, 2024; 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 36; Board number 19

Details of an independent poster presentation of an ADCT-601 preclinical study are as follows:

Title: Preclinical anti-tumorigenic evaluation of AXL targeting antibody-drug-conjugate in an adenoid cystic carcinoma cell line xenograft model